Connecticut-Specific Guidance: What Stamford Patients Should Know IV therapy in Connecticut is regulated under the supervision of licensed medical professionals
Inhibition of the EAG2-Kv2 complex mitigates cancer aggressiveness, extending survival time in mice with GBM, even in GBM resistant to TMZ [288, 556, 557]
Disclosures: Lesley Patmore: Gilead Sciences: Consultant, Lilian Yan Liang: Nothing to Disclose, Mai Kilany: Nothing to Disclose, Arno Furqium d'Almeida: Nothing to Disclose, Vincent Wong: Nothing to Disclose, Thomas Vanwolleghem: Johnson and Johnson: Advisor, GSK: Grant/Research Support, Fujirebio: Grant/Research Support, Gilead Sciences: Speaking and Teaching, Abbvie: Speaking and Teaching, Pieter Honkoop: Nothing to Disclose, Hans Blokzijl: Nothing to Disclose, zgr Muhammet Koc: Nothing to Disclose, Harry Janssen: Gilead Sciences: and consultant, Gilead Sciences: Grant/Research Support, GlaxoSmithKline: Grant/Research Support, Janssen: Grant/Research Support, Roche: Grant/Research Support, Vir Biotechnology Inc.: Grant/Research Support, Aligos: Consultant, Gilead Sciences: Consultant, GlaxoSmithKline: Consultant, Grifols: Consultant, Roche: Consultant, Vir Biotechnology Inc: Consultant, Precision Biosciences: Consultant, Matthijs Kramer: Dr Falk: Sponsoring of educational meetings, Joep de Bruijne: Nothing to Disclose, Apichat Kaewdech: Nothing to Disclose, Robert De Man: roche diagnostics: Grant/Research Support, Bart Takkenberg: Nothing to Disclose, Grace Lai-Hung Wong: AstraZeneca, Gilead Sciences, GlaxoSmithKline and Janssen,: Advisor, Abbott, AbbVie, Ascletis, Bristol-Myers Squibb, Echosens, Gi: Speaking and Teaching, Gilead Sciences: Grant/Research Support, Jordan Feld: Mirum: Consultant, AbbVie, Bluejays, Gilead, Janssen, GSK, Roche, VIR Roche: Consultant, Bluejays: Consultant, Gilead: Consultant, Janssen: Consultant, GSK: Consultant, Roche: Consultant, VIR Biotechnology: Consultant, Altimmune, AbbVie, Gilead, Jannsen, GSK, Roche, VIR Bio: Grant/Research Support, Milan Sonneveld: Nothing to Disclose 2650 REPRESENTATION OF GENDER, RACIAL, AND ETHNIC MINORITIES IN HEPATOLOGY CLINICAL TRIALS KIN LI, DO 1 , MUHAMMED BOUSO, MD 1 , MALIK MUSHANNEN, MD 1 , CARLA PELLERGRINO, MD 1 , JOSHUA HARROCH, MD 1 , GRES KARIM, MD 2 , NICHOLAS BROWN, MD 2,3,4 , ILAN WEISBERG, MD 2,3 1 NEW YORK PRESBYTERIAN - BROOKLYN METHODIST, DEPARTMENT OF MEDICINE, BROOKLYN, NY 11215 2 NEW YORK PRESBYTERIAN - BROOKLYN METHODIST, DEPARTMENT OF GASTROENTEROLOGY, BROOKLYN, NY 11215 3 WEILL CORNELL MEDICINE, DEPARTMENT OF GASTROENTEROLOGY, NEW YORK, NY 10021 4 COLUMBIA UNIVERSITY IRVING MEDICAL CENTER, DEPARTMENT OF GASTROENTEROLOGY, NEW YORK, NY 10032 Kin Li 1 Fouad Bouso 1 Malik Mushannen 1 Joshua Harroch 1 Carla Pellegrino 1 Gres Karim 1 Nicholas Brown 1 Ilan Weisberg 2 , 1 New York Presbyterian - Brooklyn Methodist, 2 Weill Cornell Medicine Background: Historically, clinical trials in the United States have overrepresented White male participants, which may lead to significant gaps in our understanding of disease manifestations and treatment responses among different demographic groups
E., Xu, W., Hamilton, A., Huss, J
doi:10.3233/JPD-161040 Mischley LK, Leverenz JB, Lau RC, et al
